Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: ramos perez j. Am J Hematol. 2021 Feb 1;96(2):E50-E53. doi: 10.1002/ajh.26044. Epub 2020 Nov 21. Am J Hematol. 2021. PMID: 33156969 Free article. No abstract available.
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: ramos perez j. Leukemia. 2021 May;35(5):1494-1499. doi: 10.1038/s41375-021-01240-2. Epub 2021 Apr 12. Leukemia. 2021. PMID: 33846541 No abstract available.
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Ramos Perez JM, et al. Leuk Lymphoma. 2022 Mar;63(3):672-675. doi: 10.1080/10428194.2021.1992757. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668451
The pharmacological management of hairy cell leukemia.
Ramos Perez J, Ravandi-Kashani F. Ramos Perez J, et al. Expert Opin Pharmacother. 2020 Aug;21(11):1337-1344. doi: 10.1080/14656566.2020.1754397. Epub 2020 May 7. Expert Opin Pharmacother. 2020. PMID: 32378970 Review.
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Shimony S, et al. Among authors: ramos perez j. Leukemia. 2024 Apr;38(4):762-768. doi: 10.1038/s41375-024-02175-0. Epub 2024 Feb 20. Leukemia. 2024. PMID: 38378841
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M. Bewersdorf JP, et al. Among authors: ramos perez j. Blood Adv. 2024 Sep 24;8(18):4845-4855. doi: 10.1182/bloodadvances.2024012858. Blood Adv. 2024. PMID: 38941537 Free PMC article.